Syngene International Limited
DSP Mutual Fund increased its stake in Syngene International from 4.61% to 4.71%, acquiring 4,26,177 shares. Based on the market price of ₹384.20, the transaction is valued at approximately ₹16.37 Cr.
India's first Contract Research Organization, Syngene provides integrated drug discovery, development, and manufacturing services through a single platform known as CRAMS. Established in 1993 as a Biocon subsidiary, the company operates extensive research and manufacturing facilities spanning multiple locations across the country. It serves global pharmaceutical and biotechnology clients with end-to-end solutions, from early-stage research through commercial-scale production.
Standalone AMC after DSP Group acquired full ownership from BlackRock in 2018. Manages over Rs 1.9 lakh crore. Known for equity funds with a clear process-first culture and minimal star manager dependency. CEO Kalpen Parekh is widely respected for transparent investor communication. DSP Small Cap Fund and DSP Midcap Fund are flagship offerings.